Evidence map›Paper›PMID 27084705›Full record

Trial reportJournal of neuro-oncology2016

Assessment of function and quality of life in a phase II multi-institutional clinical trial of fractionated simultaneous in-field boost radiotherapy for patients with 1-3 metastases.

Glenn Bauman, Slav Yartsev, David Roberge, Robert MacRae, Wilson Roa, Valerie Panet-Raymond, Laura Masucci, Brian Yaremko, David D'Souza, David Palma and 11 more

Abstract readClinical Trial, Phase IIMulticenter Study
PubMed Publisher
In one paragraph

Trial report in Journal of neuro-oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Whole-brain radiotherapy with simultaneous integrated boost in treatment of patients with brain metastases: a systematic review and meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 5 institutions in 1 country.

Glenn BaumanDivision of Radiation Oncology, London Health Sciences Centre, A4-901B, 790 Commissioners Rd. E, London, ON, N6A4L6, Canada. glenn.bauman@lhsc.on.ca.
Slav YartsevDivision of Radiation Oncology, London Health Sciences Centre, A4-901B, 790 Commissioners Rd. E, London, ON, N6A4L6, Canada.
David RobergeDepartment of Radiation Oncology, Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.
Robert MacRaeDivision of Radiation Oncology, University of Ottawa, Ottawa, ON, Canada.
Wilson RoaDepartment of Radiation Oncology, Cross Cancer Institute, Edmonton, AB, Canada.
Valerie Panet-RaymondDepartment of Radiation Oncology, McGill University Health Centre, Montreal, QC, Canada.
Laura MasucciDepartment of Radiation Oncology, Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.
Brian YaremkoDivision of Radiation Oncology, London Health Sciences Centre, A4-901B, 790 Commissioners Rd. E, London, ON, N6A4L6, Canada.
David D'SouzaDivision of Radiation Oncology, London Health Sciences Centre, A4-901B, 790 Commissioners Rd. E, London, ON, N6A4L6, Canada.
David PalmaDivision of Radiation Oncology, London Health Sciences Centre, A4-901B, 790 Commissioners Rd. E, London, ON, N6A4L6, Canada.
Tracy SextonDivision of Radiation Oncology, London Health Sciences Centre, A4-901B, 790 Commissioners Rd. E, London, ON, N6A4L6, Canada.
Edward YuDivision of Radiation Oncology, London Health Sciences Centre, A4-901B, 790 Commissioners Rd. E, London, ON, N6A4L6, Canada.
Jason R PantarottoDivision of Radiation Oncology, University of Ottawa, Ottawa, ON, Canada.
Belal AhmadDivision of Radiation Oncology, London Health Sciences Centre, A4-901B, 790 Commissioners Rd. E, London, ON, N6A4L6, Canada.
Barbara FisherDivision of Radiation Oncology, London Health Sciences Centre, A4-901B, 790 Commissioners Rd. E, London, ON, N6A4L6, Canada.
A Rashid DarDivision of Radiation Oncology, London Health Sciences Centre, A4-901B, 790 Commissioners Rd. E, London, ON, N6A4L6, Canada.
Carole LambertDepartment of Radiation Oncology, Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.
Gregory PondDepartment of Oncology, Department of Oncology, McMaster University, Hamilton, ON, Canada.
Larry StittDivision of Radiation Oncology, London Health Sciences Centre, A4-901B, 790 Commissioners Rd. E, London, ON, N6A4L6, Canada.
Keng Yeow TayDepartment of Diagnostic Radiology, London Health Sciences Centre, London, ON, Canada.
George RodriguesDivision of Radiation Oncology, London Health Sciences Centre, A4-901B, 790 Commissioners Rd. E, London, ON, N6A4L6, Canada.
London Health Sciences Centre · CACentre Hospitalier de l’Université de Montréal · CAUniversity of Ottawa · CAMcGill University Health Centre · CAMcMaster University · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We examined functional outcomes and quality of life of whole brain radiotherapy (WBRT) with integrated fractionated stereotactic radiotherapy boost (FSRT) for brain metastases treatment. Eighty seven people with 1-3 brain metastases (54/87 lung primary, 42/87 single brain metastases) were enrolled on this Phase II trial of WBRT (30 Gy/10) + simultaneous FSRT, (60 Gy/10). Median overall follow-up and survival was 5.4 months, 6 month actuarial intra-lesional control was 78 %; only 1 patient exhibited grade 4 toxicity (worsened seizures); most treatment related toxicity was grade 1 or 2; 2/87 patients demonstrated asymptomatic radiation necrosis on follow-up imaging. Mean (Min-Max) baseline KPS, Mini Mental Status Exam (MMSE) and FACT-BR quality of life were 83 (70-100), 28 (21-30) and 143 (98-153). Lower baseline MMSE (but not KPS or FACT-Br) was associated with worse survival after adjusting for age, number of metastases, primary and extra-cranial disease status. Crude rates of deterioration (>10 points decrease from baseline for KPS and FACT-Br, MMSE fall to <27) ranged from 26 to 38 % for KPS, 32-59 % for FACT-Br and 0-16 % for MMSE depending on the time-point assessed with higher rates generally noted at earlier time points (≤6 months post-treatment). Using a linear mixed models analysis, significant declines from baseline were noted for KPS and FACT-Br (largest effects at 6 weeks to 3 months) with no significant change in MMSE. The effects on function and quality of life of this integrated treatment of WBRT + simultaneous FSRT were similar to other published series combining WBRT + radiosurgery.

Indexed as

RadiosurgeryAdultAgedAged, 80 and overBrain NeoplasmsFemaleFollow-Up StudiesHumansLinear ModelsLung NeoplasmsMaleMiddle AgedQuality of LifeSuperior Sagittal SinusSurvival AnalysisTreatment OutcomeBrain metastasesPhase II TrialStereotactic radiotherapy

Identifiers

PMID27084705
OpenAlexW2336230752

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.